AU2003292936A1 - Therapeutic formulations for the treatment of beta-amyloid related diseases - Google Patents

Therapeutic formulations for the treatment of beta-amyloid related diseases Download PDF

Info

Publication number
AU2003292936A1
AU2003292936A1 AU2003292936A AU2003292936A AU2003292936A1 AU 2003292936 A1 AU2003292936 A1 AU 2003292936A1 AU 2003292936 A AU2003292936 A AU 2003292936A AU 2003292936 A AU2003292936 A AU 2003292936A AU 2003292936 A1 AU2003292936 A1 AU 2003292936A1
Authority
AU
Australia
Prior art keywords
amyloid
peptide
agent
group
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003292936A
Other languages
English (en)
Inventor
Francesco Bellini
Francine Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Neurochem International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem International Ltd filed Critical Neurochem International Ltd
Publication of AU2003292936A1 publication Critical patent/AU2003292936A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
AU2003292936A 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases Abandoned AU2003292936A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43637902P 2002-12-24 2002-12-24
US60/436,379 2002-12-24
US48221403P 2003-06-23 2003-06-23
US60/482,214 2003-06-23
PCT/CA2003/002021 WO2004058239A1 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases

Publications (1)

Publication Number Publication Date
AU2003292936A1 true AU2003292936A1 (en) 2004-07-22

Family

ID=32685452

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003292936A Abandoned AU2003292936A1 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2003291910A Ceased AU2003291910B2 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003291910A Ceased AU2003291910B2 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases

Country Status (13)

Country Link
US (1) US20060135403A1 (es)
EP (2) EP1581203A1 (es)
JP (2) JP2006525226A (es)
KR (1) KR20050101537A (es)
AU (2) AU2003292936A1 (es)
BR (1) BR0317747A (es)
CA (2) CA2511599A1 (es)
EA (1) EA012325B1 (es)
IL (1) IL169338A0 (es)
MX (1) MXPA05006940A (es)
NO (1) NO20053077L (es)
NZ (1) NZ541282A (es)
WO (2) WO2004058239A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248995B2 (en) * 2003-06-23 2010-01-07 Bhi Limited Partnership Pharmaceutical formulations of amyloid inhibiting compounds

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE437641T1 (de) 2003-05-15 2009-08-15 Roskamp Res Llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
NZ544684A (en) * 2003-06-23 2009-10-30 Bellus Health Int Ltd Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
MXPA05013692A (es) * 2003-06-23 2006-03-13 Neurochem Int Ltd Metodos para tratar trastornos por acumulacion de proteina.
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2537093C (en) * 2003-08-29 2013-11-12 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
TWI357414B (en) 2003-12-17 2012-02-01 Wyeth Llc Aβ immunogenic peptide carrier conjugates and meth
JP2007532624A (ja) * 2004-04-14 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルツハイマー病の治療のための療法組合せ
CA2582385A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP4717537B2 (ja) * 2004-08-31 2011-07-06 株式会社 資生堂 皮膚外用組成物
WO2006059252A2 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US7420071B2 (en) * 2005-05-04 2008-09-02 Uchicago Argonne, Llc Thermally stable surfactants and compositions and methods of use thereof
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
EP2808032B1 (en) 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
NO346055B1 (no) 2005-12-12 2022-01-24 Ac Immune Sa Antigen konstruksjon, vaksinesammensetning og fremgangsmåte for produksjon derav.
AU2006342958A1 (en) 2005-12-22 2007-11-08 Bellus Health (International) Limited Treatment of renal disorders, diabetic nephropathy and dyslipidemias
WO2007084818A2 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
MX2009000476A (es) 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
ME01758B (me) 2006-07-14 2014-09-20 Genentech Inc Humanizirano protutijelo protiv amiloida beta
WO2009019534A2 (en) * 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
EP2160352A2 (en) * 2007-05-24 2010-03-10 Simone Arca Method for the production of binary clathrate hydrates of hydrogen
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
JP5436414B2 (ja) 2007-06-12 2014-03-05 エーシー イミューン ソシエテ アノニム モノクローナル抗βアミロイド抗体
WO2009012571A1 (en) 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
BRPI0818623A2 (pt) 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
CN101883564B (zh) 2007-10-05 2013-10-16 阿尔茨海默病学会美国公司 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010042603A1 (en) * 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
KR20120004994A (ko) 2009-03-18 2012-01-13 에이씨 이뮨 에스.에이. 치료적 이용 방법
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5051274B2 (ja) * 2009-06-04 2012-10-17 住友化学株式会社 加硫ゴムが有する粘弾性特性を改善させるためのｓ−（３−アミノプロピル）チオ硫酸および／またはその金属塩の使用
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA2812865C (en) 2010-10-07 2021-01-26 Ac Immune S.A. Phosphospecific antibodies recognising tau
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
GEP201706786B (en) 2011-01-10 2017-12-11 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer's disease
US9499488B2 (en) * 2011-07-11 2016-11-22 Beth Israel Deaconess Medical Center, Inc. Vitamin D receptor agonists and uses thereof
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
CN104080806B (zh) 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
CA3132310C (en) * 2012-08-07 2024-01-09 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
US10662193B2 (en) 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US10314911B2 (en) * 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
SI3057589T1 (sl) * 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (s)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini
EP3054950B1 (en) * 2014-05-09 2017-08-02 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
AU2016270858B2 (en) 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
US10590070B2 (en) * 2015-08-10 2020-03-17 Alzheon, Inc. Compositions and methods for treating and preventing neurodegenerative disorders
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
ITUA20161679A1 (it) 2016-03-15 2017-09-15 Neuraxpharm Italy S P A Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
US11970521B2 (en) 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AU2018230478A1 (en) 2017-03-09 2019-09-12 Diamedica Inc. Dosage forms of tissue kallikrein 1
TW202400231A (zh) 2017-03-28 2024-01-01 美商建南德克公司 治療神經退化性疾病之方法
CA3061340A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
KR101917128B1 (ko) 2017-04-28 2018-11-09 강원대학교산학협력단 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물
US20190015361A1 (en) * 2017-07-17 2019-01-17 Maxwell Biosciences, Inc. Polytherapy modulating cathelicidin gene exprtession modulation for the treatment of alzheimer's disease and other conditions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
US11958889B2 (en) 2017-10-25 2024-04-16 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
CR20200326A (es) 2018-01-05 2020-12-09 Ac Immune Sa Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer.
BR112020018868A2 (pt) 2018-03-28 2021-01-26 Axon Neuroscience Se métodos baseados em anticorpo para detectar e tratar doença de alzheimer
TWI743484B (zh) 2018-06-04 2021-10-21 瑞士商Ａｃ免疫公司 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物
US20210214371A1 (en) 2018-06-04 2021-07-15 Ac Immune Sa Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
KR20200086198A (ko) 2019-01-08 2020-07-16 주식회사 솔고 바이오메디칼 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물
US20200222400A1 (en) * 2019-01-16 2020-07-16 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
EP3941477A1 (en) 2019-03-01 2022-01-26 AC Immune SA Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
CA3138008A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用
KR20210133603A (ko) 2020-04-29 2021-11-08 정지영 굼벵이를 포함하는 치매 예방 또는 치료용 조성물
WO2021231566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
AR123730A1 (es) 2020-10-15 2023-01-04 Ac Immune Sa Compuestos novedosos
KR102598904B1 (ko) * 2022-12-16 2023-11-06 닥터노아바이오텍 주식회사 콜린에스터라제 억제제의 부작용 예방 또는 치료용 조성물
KR20240049296A (ko) 2021-08-27 2024-04-16 제넨테크, 인크. 타우 병증을 치료하는 방법
CN115624555A (zh) * 2022-02-24 2023-01-20 中国药科大学 猪去氧胆酸在制备抗抑郁药物中的应用
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
KR20230147988A (ko) * 2022-04-15 2023-10-24 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
EP0691844A1 (en) * 1993-03-29 1996-01-17 Queen's University At Kingston Method for treating amyloidosis
AU1072897A (en) * 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
NZ550199A (en) * 1998-02-11 2008-07-31 Bellus Health Int Ltd Treatment of inflammation, abeta-induced cell toxicity, neuronal cell death or neuronal cell loss in subjects suffering from alzheimer's disease
GB9805561D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
JP2002515429A (ja) * 1998-05-15 2002-05-28 ネウロケム、インク ニューロン細胞死を調節する方法
AU781292B2 (en) * 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
EP1173480B1 (en) * 1999-05-05 2008-01-16 Neurochem (International) Limited Stereoselective antifibrillogenic peptides
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US6670399B2 (en) * 1999-12-23 2003-12-30 Neurochem (International) Limited Compounds and methods for modulating cerebral amyloid angiopathy
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
EP1538163A3 (en) * 2000-11-01 2005-06-15 Insight Biotechnology Limited Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248995B2 (en) * 2003-06-23 2010-01-07 Bhi Limited Partnership Pharmaceutical formulations of amyloid inhibiting compounds

Also Published As

Publication number Publication date
NZ541282A (en) 2009-02-28
MXPA05006940A (es) 2006-02-22
WO2004058258A1 (en) 2004-07-15
KR20050101537A (ko) 2005-10-24
IL169338A0 (en) 2007-07-04
NO20053077L (no) 2005-09-22
CA2511606A1 (en) 2004-07-15
CA2511599A1 (en) 2004-07-15
AU2003291910B2 (en) 2009-10-01
WO2004058239A1 (en) 2004-07-15
EA200501023A1 (ru) 2005-12-29
JP2006525226A (ja) 2006-11-09
EP1581203A1 (en) 2005-10-05
NO20053077D0 (no) 2005-06-23
AU2003291910A1 (en) 2004-07-22
US20060135403A1 (en) 2006-06-22
EP1585520A1 (en) 2005-10-19
EA012325B1 (ru) 2009-08-28
JP2006512417A (ja) 2006-04-13
BR0317747A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
AU2003292936A1 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
JP6174727B2 (ja) 治療的特性を有するβ１〜４２特異的モノクローナル抗体
JP5436414B2 (ja) モノクローナル抗βアミロイド抗体
ES2445590T3 (es) Uso de anticuerpo anti-amiloide beta en enfermedades oculares
JP2018021033A (ja) ペプチド治療薬およびその使用方法
US20040028673A1 (en) Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
EA019334B1 (ru) Способы и композиции для лечения амилоидных заболеваний
JPH05501868A (ja) 神経精神薬理剤としてのｎ―メチル―ｄ―アスパラギン酸レセプター複合体のストリキニーネ非感受性グリシン調節部位の部分的作動剤
EP2863935B1 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma
ES2436112T3 (es) Anticuerpo humanizado
JP7059192B2 (ja) 神経変性疾患の治療に使用するためのイグメシン
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
EP4252750A1 (en) Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease
JP7315964B2 (ja) Ａβタンパク質特異的産生抑制剤
JP2007518786A (ja) アミロイドーシスを治療するためのアミジン誘導体
WO2023288284A1 (en) Inhibitors of amyloid beta oligomerization and therapeutic uses thereof
CA3234071A1 (en) Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023133321A1 (en) Small molecule peptidomimetic for the treatment of tauopathies
JP2017132742A (ja) Ａβオリゴマー特異的抗体の新規薬理用途
CA2603127A1 (en) Use of spirostenols to treat mitochondrial disorders

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application